Promising drug by UAlberta researchers could save millions of lives.
Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.
Heart specialist Gavin Oudit and his research team discovered a molecule—angiotensin converting enzyme 2 (ACE2)—that works to restore balance to the pathways responsible for chronic and acute heart failure, including in patients with advanced heart failure who underwent heart transplants.
In conducting their research, Oudit and his team used genetic mapping technology to discover to an extent not seen before how the renin-angiotensin system (RAS)—which regulates the body’s sodium balance, fluid volume and blood pressure—is at play in both acute and chronic heart failure.
It led to the creation of recombinant human ACE2, a new drug that was manufactured by Apeiron Biologics in collaboration with Oudit. It was bought by GlaxoSmithKline, which recently successfully completed phase II clinical trials that tested for the safety and efficacy of the drug on hundreds of patients. The new drug is expected to be on the market in the next three to five years.
Oudit added that using mapping technology has also made it possible to individualize the dose a patient needs, allowing for a truly personalized treatment plan for heart failure patients in the future. The study also broke ground by showing how ACE2 can be used in heart transplant patients with heart failure.
About six million Canadians will develop heart failure, a common condition that most often happens after the heart has been damaged or weakened by heart attack or stroke. According to the Canadian Heart and Stroke Foundation, the two most common causes of heart failure are heart attacks and high blood pressure. When someone has heart failure, the heart either can’t accept the inflow of blood or pump it out, or both.
“This research is a terrific example of how the university works together synergistically to develop world-class research and translate that into medicines that impact patient outcomes,” added Oudit.
Learn more: New hope for treating heart failure
Receive an email update when we add a new ARTIFICIAL SYNAPSES article.
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Cancer to overtake heart disease as leading killer of affluent Americans on November 12, 2018 at 7:55 pm
MONDAY, Nov. 12, 2018 -- Cancer is expected to overtake heart disease as the leading cause of death for well-off Americans by 2020. The expected shift owes to advances in technology and drugs that are ... […]
- Coronary calcium screening better predicts heart disease risk, research finds on November 12, 2018 at 3:29 pm
(CNN) - Last year, President Donald Trump's doctors screened him for heart disease using a test unfamiliar to many Americans. Now, research shows that that test, either alone or combined with other ev... […]
- Cancer surpasses heart disease as leading cause of death in many US counties on November 12, 2018 at 2:01 pm
An important transition is happening across the United States: Cancer was the leading cause of death in more counties in 2015 than 13 years earlier, a new study finds. However, the opposite was true f... […]
- PIONEER-HF: Sacubitril/Valsartan Bests ACE Inhibitor for Biomarker Benefit in Stabilized Acute Heart Failure on November 12, 2018 at 12:23 pm
CHICAGO — If sacubitril/valsartan (Entresto, Novartis) remains slow to catch on in chronic heart failure (HF), despite earning support in the guidelines after the PARADIGM-HF trial, a new randomized t... […]
- Risk score-guided care reduces mortality rate in heart failure patients by nearly 50 percent on November 12, 2018 at 12:04 pm
New team-based care guided by a personalized risk score for heart failure patients reduced the mortality rate of high-risk heart failure patients by nearly 50 percent, according to new research from t... […]
- Don't count on vitamin D or fish oil supplements to reduce your risk of cancer or heart disease on November 12, 2018 at 11:40 am
A widely anticipated study has concluded that neither vitamin D nor fish oil supplements prevent cancer or serious heart-related problems — such as heart attacks and strokes — in healthy older people. ... […]
- Patients With Common Heart Failure More Likely to Have Lethal Heart Rhythms on November 12, 2018 at 10:49 am
Newswise — NOV. 10, 2018 - Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely ... […]
- Diabetes drug might also ease heart failure risks on November 12, 2018 at 5:58 am
(HealthDay)—The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga (dapagliflozin ... […]
- Diabetes drug might also ease heart failure risk on November 11, 2018 at 9:22 am
SUNDAY, Nov. 11, 2018-- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga saw their ... […]
via Bing News